Select Publications

Cameron D et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;[Epub ahead of print]. Abstract

Dang CT et al. Preliminary safety results of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BCA). Proc ASCO 2008;Abstract 518.

Dang C et al. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. J Clin Oncol 2008;26(8):1216-22. Abstract

Geyer CE et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355(26):2733-43. Abstract

Hayes DF et al. Angiogenesis as targeted breast cancer therapy. Breast 2007;16(Suppl 2):17-9. Abstract

Lin NU et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008;26(12):1993- 9. Abstract

Miles D. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. Proc ASCO 2008;Abstract LBA1011.

Miles D. Bevacizumab in first-line treatment of metastatic breast cancer. Drugs 2007;67(12):1800-1. Abstract

Miller K et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357(26):2666-76. Abstract

Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-9. Abstract

O’Shaughnessy J et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. Proc ASCO 2008;Abstract 1015.

Traina TA et al. Phase I study of a novel capecitabine schedule based on the Norton- Simon mathematical model in patients with metastatic breast cancer. J Clin Oncol 2008;26(11):1797-802. Abstract

 

 

 

 

 

 

 

 

Home · Search

EDITOR
Neil Love, MD

INTERVIEWS

Paul E Goss, MD, PhD
- Select publications

Martine J Piccart-Gebhart, MD, PhD
- Select publications

TUMOR PANEL CASE DISCUSSION
- Select publications

INTERVIEWS (continued)

Erica L Mayer, MD, MPH
- Select publications

Maria Theodoulou, MD
- Select publications

 

Breast Cancer Update:
A CME Audio Series and Activity

Faculty Disclosures

Editor's Office